3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
219
Neoplasms
15
Neoplasm Metastasis
12
Carcinoma, Intraductal, Noninfiltrating
10
Breast Neoplasms, Male
7
Breast Diseases
7
Breast Carcinoma In Situ
7
Advanced Breast Cancer
6
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Neoplasms by Site
3
Breast Cancer Metastatic
3
Uterine Cervical Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasm Female
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Sexual Dysfunction, Physiological
1
Seizures
1
Sarcoma
1
Recurrence
1
Quality of Life
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteoporosis
1
Multiple Endocrine Neoplasia Type 1
1
Low Grade Serous Ovarian Cancer
1
Interventions
Zoledronic Acid
6
Risedronic Acid
5
Calcium
4
Vitamin D
3
Denosumab
3
Letrozole
2
Toremifene
1
Nutrition Assessment
1
Kyphoplasty
1
Ibandronic Acid
1
Health Promotion
1
Geritol
1
Exercise Movement Techniques
1
Exercise
1
Cholecalciferol
1
Calcium Carbonate
1
Aromatase Inhibitors
1
Anastrozole
1
ARQ 197
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bone Diseases, Metabolic
×
Anastrozole
×
Clear all
NCT00082277
2011-01-26
SABRE
AstraZeneca
Phase 4
Completed
237 enrolled